List of Arakoda drug patents

Arakoda is owned by 60 Degrees Pharms.

Arakoda contains Tafenoquine Succinate.

Arakoda has a total of 2 drug patents out of which 0 drug patents have expired.

Arakoda was authorised for market use on 08 August, 2018.

Arakoda is available in tablet;oral dosage forms.

Arakoda can be used as for the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose.

Drug patent challenges can be filed against Arakoda from July, 2022.

The generics of Arakoda are possible to be released after 02 December, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10342791 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(12 years from now)

US10888558 60 DEGREES PHARMS Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Dec, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2023

Drugs and Companies using TAFENOQUINE SUCCINATE ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 08 August, 2018

Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose

Dosage: TABLET;ORAL

More Information on Dosage

ARAKODA family patents

6

United States

2

Australia

1

Hong Kong

1

Canada

1

Singapore

1

China

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in